NGL Fine Chem Ltd.

BSE: NGLFINE524774ISIN INE887E01022

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹2,695.20+135.00 (+5.27%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹3,595.00
52W low: ₹1,261.00
Off 52W high: -25.03%
1M return: -10.45%
3M return: -21.74%
6M return: +1.52%
1Y return: +65.35%
20D avg volume: 224
50 DMA: ₹2,784.66
200 DMA: ₹2,607.63

Key ratios Consolidated

Market cap: ₹1,665 Cr
Current price: ₹2,695.20
52W high / low: ₹3,595.00 / ₹1,261.00
Face value: ₹5.00
P/E: 29.11
P/B: 5.06
EPS (TTM): ₹92.58
Book value / share: ₹532.91
ROE: —
ROCE: 17.20%
Operating margin: —
Net margin: —
Debt / equity: 0.33
Net debt: ₹105.61 Cr
Interest cover: 15.18
Dividend yield: 0.06%
Dividend / share (TTM): ₹1.75
Payout: 1.89%
Cash conversion cycle: 99.5 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	139.16	149.23	127.51	120.26	104.19	94.97	89.10	93.48	90.75	99.76	87.95	80.18
	7.43	2.46	4.61	2.05	6.35	-0.97	0.13	5.12	5.88	3.68	3.68	3.22
	146.59	151.69	132.12	122.31	110.54	94.01	88.97	98.60	96.64	103.44	91.63	83.40
	122.11	133.88	111.45	109.35	98.70	92.95	87.70	85.27	84.85	87.35	77.30	69.46
	80.47	67.30	62.70	61.89	55.40	51.18	47.93	41.80	41.55	51.77	46.07	40.49
	0.00	0.00	0.00	0.00	-3.51	0.00	—	—	—	—	—	—
	18.92	16.96	17.09	15.70	15.76	14.25	14.66	14.72	11.92	12.09	11.52	10.90
	0.99	1.01	1.07	1.16	1.22	0.97	0.60	0.32	0.44	0.49	0.28	0.36
	5.25	5.05	5.18	5.08	4.27	3.32	3.10	3.03	3.00	2.92	2.94	2.89
	35.54	39.96	28.60	30.14	25.56	26.60	25.81	23.03	22.31	24.54	21.31	19.11
	24.48	17.81	20.67	12.96	11.84	1.06	1.26	13.33	11.79	16.09	14.33	13.94
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	24.48	17.81	20.67	12.96	11.84	1.06	1.26	13.33	11.79	16.09	14.33	13.94
	6.08	4.33	4.98	3.34	2.60	0.52	0.01	3.52	2.57	3.77	4.30	3.46
	18.40	13.49	15.69	9.63	9.24	0.54	1.28	9.81	9.22	12.32	10.03	10.48
	29.78	21.83	25.40	15.58	14.96	0.88	2.07	15.88	14.92	19.95	16.24	16.96
Key metrics
	30.72	23.87	26.92	19.20	17.33	5.35	4.96	16.68	15.23	19.50	17.55	17.19
	22.10%	16.00%	21.10%	16.00%	16.60%	5.60%	5.60%	17.80%	16.80%	19.50%	20.00%	21.40%
	13.20%	9.00%	12.30%	8.00%	8.90%	0.60%	1.40%	10.50%	10.20%	12.30%	11.40%	13.10%
	—	4.80%	—	4.10%	—	0.60%	—	—	—	—	—	—
	33.60%	57.10%	43.10%	28.60%	14.80%	-4.80%	1.30%	16.60%	—	—	—	—
	99.10%	2,398.10%	1,125.80%	-1.80%	0.20%	-95.60%	-87.20%	-6.40%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	536.16	500.95	368.26	338.69	278.08	317.50
	16.55	14.73	8.63	14.13	5.53	10.68
	552.71	515.68	376.89	352.82	283.61	328.19
	476.79	452.32	349.17	298.40	256.25	261.59
	272.36	247.22	182.41	170.81	116.41	169.67
	0.00	0.00	0.00	—	—	—
	68.67	65.50	55.55	45.12	36.87	34.85
	4.23	4.47	2.33	1.34	1.20	1.56
	20.56	19.58	12.45	11.64	11.29	10.37
	134.24	123.27	96.44	81.62	66.57	67.81
	75.92	63.37	27.71	54.42	27.36	66.60
	0.00	0.00	0.00	0.00	0.00	0.00
	75.92	63.37	27.71	54.42	27.36	66.60
	18.73	15.24	6.59	13.10	6.87	16.70
	57.21	48.13	21.12	41.32	20.50	49.90
	92.59	77.90	34.19	66.88	33.18	80.77
Key metrics
	100.71	87.42	42.49	67.40	39.85	78.53
	18.78%	17.50%	11.50%	19.90%	14.30%	24.70%
	10.67%	9.60%	5.70%	12.20%	7.40%	15.70%
	—	17.20%	9.60%	—	—	—
	40.45%	36.00%	8.70%	21.80%	-12.40%	—
	174.13%	127.90%	-48.90%	101.60%	-58.90%	—
	—	-46.53	-94.95	—	—	—
	—	0.90	1.70	—	—	—
	—	0.33	0.26	—	—	—
	—	105.61	72.58	—	—	—
	—	99.5	74.6	—	—	—
Balance sheet
	—	545.50	433.39	—	—	—
	—	276.39	235.38	—	—	—
	—	2.81	0.58	—	—	—
	—	130.88	81.55	—	—	—
	—	70.28	51.27	—	—	—
	—	29.21	28.64	—	—	—
	—	163.80	142.12	—	—	—
	—	64.61	57.52	—	—	—
	—	150.01	118.97	—	—	—
	—	108.42	73.16	—	—	—
	—	52.02	47.82	—	—	—
	—	56.40	25.34	—	—	—
	—	329.23	282.43	—	—	—
Cash flow
	—	43.32	35.82	—	—	—
	—	-70.59	-34.55	—	—	—
	—	29.55	-1.08	—	—	—
	—	89.85	130.77	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	136.71	144.75	126.33	116.84	100.86	93.02	86.83	91.41	88.03	95.61	84.81	79.44
	7.36	2.51	4.69	2.41	6.55	-0.79	0.15	5.43	6.27	4.16	4.19	3.76
	144.07	147.26	131.02	119.25	107.41	92.23	86.98	96.84	94.30	99.77	89.00	83.20
	122.33	132.38	111.65	108.59	97.70	92.59	86.17	83.41	84.30	85.53	76.20	68.69
	81.61	68.07	63.99	63.55	55.07	51.78	49.82	41.77	40.42	50.01	45.07	39.96
	0.00	0.00	0.00	0.00	-4.05	0.00	—	—	—	—	—	4.12
	17.49	15.69	15.72	14.37	14.47	12.94	13.25	13.67	10.85	10.95	10.53	10.05
	0.97	0.99	1.06	1.15	1.21	0.95	0.60	0.32	0.44	0.46	0.28	0.36
	4.43	4.24	4.35	4.26	3.45	2.53	2.30	2.30	2.14	2.06	2.07	2.02
	36.76	40.55	29.00	31.00	27.55	27.25	24.93	22.32	24.53	26.57	23.33	20.41
	21.75	14.88	19.37	10.66	9.71	-0.36	0.81	13.43	10.00	14.24	12.79	14.52
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	21.75	14.88	19.37	10.66	9.71	-0.36	0.81	13.43	10.00	14.24	12.79	14.52
	5.29	3.52	4.64	2.76	2.07	0.16	0.03	3.39	2.18	3.39	3.90	3.55
	16.45	11.35	14.74	7.90	7.64	-0.52	0.78	10.04	7.83	10.85	8.90	10.97
	26.63	18.38	23.85	12.78	12.37	-0.84	1.27	16.26	12.67	17.56	14.40	17.76
Key metrics
	27.15	20.11	24.78	16.07	14.37	3.12	3.71	16.05	12.58	16.76	15.14	16.90
	19.90%	13.90%	19.60%	13.80%	14.20%	3.40%	4.30%	17.60%	14.30%	17.50%	17.90%	21.30%
	12.00%	7.80%	11.70%	6.80%	7.60%	-0.60%	0.90%	11.00%	8.90%	11.30%	10.50%	13.80%
	—	4.10%	—	3.50%	—	0.20%	—	—	—	—	—	—
	35.50%	55.60%	45.50%	27.80%	14.60%	-2.70%	2.40%	15.10%	—	—	—	—
	115.30%	2,282.70%	1,789.70%	-21.30%	-2.40%	-104.80%	-91.20%	-8.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	524.63	488.77	359.29	328.97	275.05	318.67
	16.97	14.85	9.76	15.90	7.61	12.64
	541.60	503.63	369.05	344.87	282.67	331.31
	474.95	449.01	345.17	294.17	256.06	262.33
	277.22	249.63	183.80	166.58	116.58	170.35
	0.00	0.00	0.00	—	—	—
	63.27	60.25	50.71	41.32	34.25	33.05
	4.17	4.40	2.31	1.34	1.20	1.56
	17.28	16.30	9.27	8.15	7.90	7.67
	137.31	126.81	97.72	88.83	72.85	71.73
	66.66	54.62	23.88	50.71	26.60	68.97
	0.00	0.00	0.00	—	—	—
	66.66	54.62	23.88	50.71	26.60	68.97
	16.21	12.99	5.75	12.19	6.48	16.73
	50.44	41.63	18.13	38.52	20.12	52.25
	81.64	67.39	29.35	62.35	32.56	84.57
Key metrics
	88.11	75.32	35.46	60.20	35.70	78.20
	16.79%	15.40%	9.90%	18.30%	13.00%	24.50%
	9.61%	8.50%	5.00%	11.70%	7.30%	16.40%
	—	15.30%	8.40%	—	—	—
	40.98%	36.00%	9.20%	19.60%	-13.70%	—
	181.16%	129.60%	-52.90%	91.50%	-61.50%	—
	—	-54.34	-56.74	—	—	—
	—	0.83	0.94	—	—	—
	—	0.34	0.26	—	—	—
	—	106.97	71.61	—	—	—
	—	99.6	75.8	—	—	—
Balance sheet
	—	529.63	425.76	—	—	—
	—	265.25	229.87	—	—	—
	—	0.55	0.57	—	—	—
	—	125.47	79.77	—	—	—
	—	67.63	49.07	—	—	—
	—	28.68	7.89	—	—	—
	—	143.68	119.49	—	—	—
	—	59.68	54.16	—	—	—
	—	144.03	114.61	—	—	—
	—	107.52	72.18	—	—	—
	—	51.12	46.84	—	—	—
	—	56.40	25.34	—	—	—
	—	319.94	279.61	—	—	—
Cash flow
	—	34.73	17.02	—	—	—
	—	-64.57	-15.75	—	—	—
	—	29.87	-1.08	—	—	—
	—	89.07	73.76	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +21.12%
Sales CAGR 5Y: —
Profit CAGR 3Y: +27.43%
Profit CAGR 5Y: —
Sales YoY (TTM): +40.98%
Profit YoY (TTM): +181.16%

Consolidated

Sales CAGR 3Y: +21.68%
Sales CAGR 5Y: —
Profit CAGR 3Y: +32.91%
Profit CAGR 5Y: —
Sales YoY (TTM): +40.45%
Profit YoY (TTM): +174.13%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 72.50%

Quarter	September 2026	June 2026
Promoter %	72.50%	72.50%

Holder	Type	Holding	Previous	Change
RAJESH NARAYAN LAWANDE	Promoter	21.89%	21.89%	0.00%
RAHUL JAYANT NACHANE	Promoter	17.54%	17.54%	0.00%
SUNITA SANDEEP POTDAR	Promoter Group	13.14%	13.14%	0.00%
AJITA RAHUL NACHANE	Promoter Group	11.55%	11.55%	0.00%
PCI FERRMONE CHEMICALS INDIA PRIVATE LIMITED	Promoter Group	8.38%	8.38%	0.00%
PUSHPA NARAYAN LAWANDE	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
NGL Fine Chem Ltd.	1,665	2,695.20	29.11	17.20%	+40.45% TTM	+174.13% TTM	+65.35%

Filings & corporate actions

Recent announcements

NGL Fine Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve 1. To consider and approve the ....31 Oct 2026 · Board Meeting / Board Meeting
Intimation of receipt of SEBI Exemption order.13 Oct 2026 · Company Update / General
Compliance Certificate under Re. 74(5) SEBI (DP) Regulations5 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimaton of Closure of Trading Window28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Disclosure of Show Cause Notice received from the GST Department25 Sep 2026 · Company Update / General
Intimation Under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Commencement of Commercial Production of Phase II of Greenfield Facility at Tarapur.24 Sep 2026 · Company Update / General
This has reference to our earlier intimation dated September 10, 2026, made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with ....16 Sep 2026 · Company Update / Analyst / Investor Meet
This is to inform you that a One to One meet has been scheduled on Wednesday, September 16, 2026 with Analyst/Investor.10 Sep 2026 · Company Update / Analyst / Investor Meet
Submission of Voting Results and Scrutinizer''s Report for the 45th Annual General Meeting of the Compny27 Aug 2026 · AGM/EGM / AGM
Summary of Proceedings of the 45th Annual General Meeting of NGL Fine-Chem Limited25 Aug 2026 · AGM/EGM / AGM
Corrigendum to the 45th Annual Report for the Financial Year 2025-2620 Aug 2026 · Company Update / General
Investors Presentation - Q1FY2717 Aug 2026 · Company Update / Investor Presentation
Newspaper Publication of Financial Results for the quarter ended June 30, 2026.14 Aug 2026 · Company Update / Newspaper Publication
Board comments on fines levied by the Exchanges12 Aug 2026 · Company Update / General
Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026.12 Aug 2026 · Result / Financial Results
We wish to inform you that, the Board of Directors of the Company at their meeting held today i.e. on Wednesday, August 12, 2026 has inter-alia considered and approved the following: 1. ....12 Aug 2026 · Board Meeting / Outcome of Board Meeting
NGL Fine Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited Standalone & Consolidated ....6 Aug 2026 · Board Meeting / Board Meeting
Newspaper Advertisement - Notice of 45th Annual General Meeting, Book Closure and E-voting Information - Post Dispatch.4 Aug 2026 · Company Update / Newspaper Publication
Submission of Business Responsibility and Sustainability Reporting for FY 2025-2631 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Submission of Annual Report as per Reg. 34 (1)31 Jul 2026 · Others / Reg. 34 (1) Annual Report
Submission of Notice of 45 Annual General Meeting and Annual Report of the Company for the Financial Year 2025-2631 Jul 2026 · AGM/EGM / AGM
Submission of Newspaper Advertisement related to 45th Annual General Meeting, Book Closure and other related information - Pre Dispatch29 Jul 2026 · Company Update / Newspaper Publication
Newspaper Advertisement - Notice to the Equity Shareholders of the Company Regarding Transfer of Equity Shares to Investor Education and Protection Fund27 Jul 2026 · Company Update / Newspaper Publication
Certificate Under Reg. 74(5) of SEBI (DP) Regulations, 201813 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window29 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Transcript of the Earnings Call - Q4 & FY 2630 May 2026 · Company Update / Earnings Call Transcript
Annual Secretarial Compliance Report for FY 2025-2629 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Audio Recording of Earning Conference Call Q4 & FY2625 May 2026 · Company Update / Analyst / Investor Meet
The Newspaper Advertisements of Financial Results for the quarter and year ended March 31, 2026, published in Free Press Journal ( English) and Navshakti ( Marathi) newspaper on Saturday, ....23 May 2026 · Company Update / Newspaper Publication
Investors Presentation Q4 & FY2622 May 2026 · Company Update / Investor Presentation
19.08.2026 to 25.08.2026 (Both Days Inclusive)21 May 2026 · Corp. Action / Book Closure
The Record Date for the purpose of Annual General meeting and payment of final dividend is Tuesday, August 18, 202621 May 2026 · Corp. Action / Record Date
Outcome of Board Meeting21 May 2026 · Company Update / Change in Management
Outcome of Board Meeting Dated May 21, 202621 May 2026 · Corp Action / Dividend/AGM
Audited Financial Results ( Standalone & Consolidated) Along with Statutory Auditor''s Report21 May 2026 · Result / Financial Results
Outcome of the Board Meeting held on Thursday, May 21, 202621 May 2026 · Board Meeting / Outcome of Board Meeting
NGL Fine Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Further to our communication ....20 May 2026 · Board Meeting / Board Meeting
Intimation of schedule of Earning Conference Call to discuss Q4 & FY26 Results19 May 2026 · Company Update / Analyst / Investor Meet
NGL Fine Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve we wish to inform you that a ....17 May 2026 · Board Meeting / Board Meeting
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2026.6 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.7500	18 Aug 2026	18 Aug 2026	—
Final Dividend - Rs. - 1.7500	12 Aug 2025	12 Aug 2025	—
Final Dividend - Rs. - 1.7500	16 Aug 2024	16 Aug 2024	—

Board meetings

6 Nov 2026 Board Meeting - Financial Results
12 Aug 2026 Board Meeting - Financial Results